Cris Frangold
Cris Frangold
Stop FollowingCris Frangold
View as an RSS Feed
View Cris Frangold's Articles BY TICKER:
AAPL,
ABT,
ABX,
ADBE,
AGNC,
AMZN,
APA,
APC,
ARR,
ATPG,
AXP,
AZN,
BAC,
BBRY,
BHP,
BIDU,
BMY,
BP,
C,
CFTMF.PK,
CHK,
CHL,
CIM,
CMG,
CMO,
COF,
COG,
COP,
CSCO,
CTL,
CVX,
CYS,
DFS,
DVN,
DX,
EMC,
EOG,
ESRX,
F,
FB,
FCX,
FSLR,
FTR,
GE,
GG,
GM,
GOOG,
GSK,
HPQ,
HTS,
IDIX,
INO,
INTC,
JNJ,
JPM,
KO,
KOG,
LLY,
LMCA,
LNVGY.PK,
LPTN,
LULU,
MCD,
MO,
MRK,
MRO,
MSFT,
MU,
MYL,
NBL,
NEM,
NFLX,
NFX,
NLY,
NOK,
NVS,
ONCS.OB,
ONVO.PK,
ORCL,
OXY,
P,
PFE,
PMT,
RIO,
S,
SD,
SIRI,
SLW,
SPPI,
SSNLF.PK,
T,
USB,
VALE,
VLO,
VRTX,
VRX,
VVUS,
VZ,
WFC,
WIN,
WM,
WMT,
XOM,
YHOO
- BHP Billiton: Uranium Sale Will Solidify Core Growth By 2013
- Rio Tinto Poised For Stellar Growth On Indian Diamond Mine
- Diverse Stocks In Modern Radiotherapy
- Eli Lilly: New Drug Nightmares Will Sink Stock In 2013
- SandRidge Energy: Get In Now While The Stock Is Deeply Undervalued
- Google: Not A One Trick Pony
- Devon Energy: Ready To Climb Higher On Production Increases In 2013
- Silver Wheaton: Defense From Currency Fluctuations
- Adobe: A Smart Play On Streaming Video
- Can You Rely On General Electric?
- New Reasons To Have Faith In Nokia's Recovery
- EMC Corporation: Ready To Jump $4 By 2013
- Why You Should Remain Bullish On Chevron
- Kodiak: A Prime Acquisition Target In Overcrowded Williston
- EMC Corporation: This Hidden Gem Is A Buy Now
- EOG Resources Is Ready To Climb Higher In 2013
- Chesapeake Could Slip To $13 Lows By 2013
- GE: Don't Underestimate This Blue-Chip
- Nokia Could Soar To $5 On Successful Release
- Analysts Are Wrong On Exxon Mobil
- Generics Will Drive Mylan Higher By 2013
- Valero Energy: Hurricane Insurance For Your Portfolio?
- Discover: Profit From This Hidden Value Play Now
- Will Drug Discounts Pay Off For Pfizer?
- BP Range-Bound Despite Efforts
- Anadarko: Deeply Undervalued At $69
- Merck Now A Strong Value Buy
- Profit From Marathon's Latest Moves In Kurdistan
- Chevron: A Beacon Amid Weather Carnage?
- 5 Tablet War Winners And Losers To Watch Closely
- Bristol-Myers Squibb: Amylin Acquisition Will Pay Off In The Long Term
- Novartis: New Drugs Will Lead Stock Higher By 2013